Cargando…
HIV envelope antibodies and TLR7 agonist partially prevent viral rebound in chronically SHIV-infected monkeys
A key challenge for the development of a cure to HIV-1 infection is the persistent viral reservoir established during early infection. Previous studies using Toll-like receptor 7 (TLR7) agonists and broadly neutralizing antibodies (bNAbs) have shown delay or prevention of viral rebound following ant...
Autores principales: | Moldt, Brian, Chandrashekar, Abishek, Borducchi, Erica N., Nkolola, Joseph P., Stephenson, Heather, Nagel, Mark, Hung, Magdeleine, Goldsmith, Joshua, Pace, Craig S., Carr, Brian, Thomsen, Nathan D., Blair, Wade S., Geleziunas, Romas, Barouch, Dan H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9067686/ https://www.ncbi.nlm.nih.gov/pubmed/35452496 http://dx.doi.org/10.1371/journal.ppat.1010467 |
Ejemplares similares
-
Antibody and TLR7 Agonist Delay Viral Rebound in SHIV-Infected Monkeys
por: Borducchi, Erica N., et al.
Publicado: (2018) -
Origin of rebound virus in chronically SIV-infected Rhesus monkeys following treatment discontinuation
por: Liu, Po-Ting, et al.
Publicado: (2020) -
Therapeutic efficacy of combined active and passive immunization in ART-suppressed, SHIV-infected rhesus macaques
por: Walker-Sperling, Victoria E. K., et al.
Publicado: (2022) -
Therapeutic Efficacy of Potent Neutralizing HIV-1-Specific Monoclonal Antibodies in SHIV-Infected Rhesus Monkeys
por: Barouch, Dan H., et al.
Publicado: (2013) -
Long-acting capsid inhibitor protects macaques from repeat SHIV challenges
por: Vidal, Samuel J., et al.
Publicado: (2021)